Back to All Topics
Research
Research Article
2 min read
Liver and Kidney Impact Comparison
Comparative analysis of hepatic and renal effects across compound classes.
Backed by 1 reference
Introduction
Organ toxicity profiles differ markedly between performance-enhancing compounds.
Liver Impact Comparison
Hepatotoxicity Risk
| Compound Type | Risk Level | Mechanism | Markers |
|---|---|---|---|
| 17-alpha alkylated steroids | High | Direct toxicity | Elevated liver enzymes |
| Injectable steroids | Low | Minimal hepatic metabolism | Usually normal |
| SARMs | Variable | Hepatic metabolism | Variable elevation |
| Peptides | Very Low | Non-hepatic metabolism | Normal |
Liver Effects by Duration
| Compound | Short-term | Medium-term | Long-term |
|---|---|---|---|
| Oral steroids | Enzyme elevation | Cholestasis possible | Adenoma risk |
| Injectable steroids | Minimal | Minimal | Lipid changes |
| SARMs | Variable | Limited data | Unknown |
| Peptides | None observed | None observed | None observed |
Kidney Impact Comparison
Nephrotoxicity Profile
| Compound Type | Direct Risk | Indirect Risk | Monitoring |
|---|---|---|---|
| Steroids | Low | Blood pressure-mediated | Periodic |
| SARMs | Unknown | Limited data | Prudent |
| GH/peptides | Very low | Minimal | Basic |
| High protein intake | Low-Moderate | Combined effect | Regular |
Kidney Function Markers
| Marker | Steroids | SARMs | Peptides |
|---|---|---|---|
| Creatinine | May raise (muscle mass) | Usually normal | Normal |
| BUN | May raise | Usually normal | Normal |
| GFR | Usually preserved | Usually preserved | Normal |
| Proteinuria | Rare | Not documented | Not documented |
Protective Strategies
| Strategy | Liver | Kidney | Both |
|---|---|---|---|
| Hydration | Moderate | High | Yes |
| Avoid alcohol | Critical | Helpful | Yes |
| Limit NSAIDs | Helpful | Critical | Yes |
| Regular monitoring | Essential | Important | Yes |
| Cycle length limits | Critical for oral | Less critical | Yes |
Conclusion
Peptides show favorable safety profile for liver and kidney compared to oral steroids.
Comparison table
| Dimension | Peptides | SARMs | Traditional protocols |
|---|---|---|---|
| Mechanism | Pathway-specific signaling | Androgen or repair pathway | Variable by protocol |
| Primary use case | Targeted research question | Performance or repair comparison | Baseline comparator |
| Typical dose range | Compound-specific | Compound-specific | Unknown |
| Half-life | Varies by peptide | Varies by compound | Unknown |
| Common side effects | Injection reactions | Hormone or tissue risk | Protocol-dependent |
| WADA status | Check current list | Often prohibited | Check current list |
| Evidence strength | low/medium | medium | low |
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.